keyword
MENU ▼
Read by QxMD icon Read
search

Erlotinib

keyword
https://www.readbyqxmd.com/read/28819442/interferon-%C3%AE-promotes-the-expression-of-cancer-stem-cell-markers-in-oral-squamous-cell-carcinoma
#1
Hailong Ma, Shufang Jin, Wenyi Yang, Zhuowei Tian, Shuli Liu, Yang Wang, Ge Zhou, Mei Zhao, Shalva Gvetadze, Zhiyuan Zhang, Jingzhou Hu
Objectives: IFNα can stimulate an antitumor immune response and has a direct inhibition on cancer cells. This study is to test whether IFNα can activate dormant cancer stem cell (CSC) in oral squamous cell carcinoma (OSCC) to facilitate their elimination by chemotherapy. Materials and methods: Nude mouse transplantation tumor model was established and administrated with IFNα and saline. The influence on CD44 and ALDH1A1 expression under IFNα treatment was detected by in vivo experiments. Flow cytometry, western blot, and immunofluorescence were used to detect the expression of CD44 and ALDH1A1 after INFa treatment in OSCC cell lines...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28817370/conko-005-adjuvant-chemotherapy-with-gemcitabine-plus-erlotinib-versus-gemcitabine-alone-in-patients-after-r0-resection-of-pancreatic-cancer-a-multicenter-randomized-phase-iii-trial
#2
Marianne Sinn, Marcus Bahra, Torsten Liersch, Klaus Gellert, Helmut Messmann, Wolf Bechstein, Dirk Waldschmidt, Lutz Jacobasch, Martin Wilhelm, Bettina M Rau, Robert Grützmann, Arndt Weinmann, Georg Maschmeyer, Uwe Pelzer, Jens M Stieler, Jana K Striefler, Michael Ghadimi, Sven Bischoff, Bernd Dörken, Helmut Oettle, Hanno Riess
Purpose Gemcitabine is standard of care in the adjuvant treatment of resectable pancreatic ductal adenocarcinoma (PDAC). The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with gemcitabine has shown efficacy in the treatment of advanced PDAC and was considered to improve survival in patients with primarily resectable PDAC after R0 resection. Patients and Methods In an open-label, multicenter trial, patients were randomly assigned to one of two study arms: gemcitabine 1,000 mg/m(2) days 1, 8, 15, every 4 weeks plus erlotinib 100 mg once per day (GemErlo) or gemcitabine (Gem) alone for six cycles...
August 17, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28807321/folliculitis-decalvans-caused-by-bacterial-superinfection-secondary-to-erlotinib
#3
A Sahuquillo-Torralba, B Escutia-Muñoz, M Rodríguez-Serna, R Botella-Estrada
No abstract text is available yet for this article.
August 11, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28802850/thermo-sensitive-chitosan-copolymer-gold-hybrid-nanoparticles-as-a-nanocarrier-for-delivery-of-erlotinib
#4
Marziyeh Fathi, Parham Sahandi Zangabad, Jaleh Barar, Ayuob Aghanejad, Hamid Erfan-Niya, Yadollah Omidi
Here, using (poly(N-isopropylacrylamide)-co-oleic acid)-g-chitosan ((PNIPAAm-co-OA)-g-CS), CS copolymer-gold hybrid nanoparticles (CGH NPs) were synthesized by autoreduction of auric cations (HAuCl4) in aqueous solution in the absence of any other reducing agent. The engineered thermo-sensitive CS copolymer with free amino groups could reduce auric cations and stabilized the resultant NPs. CGH NPs were prepared using different concentrations of CS copolymer (0.1-1% w/v) and HAuCl4 (50-500μL, 0.2% w/v). They were characterized in terms of structure, surface Plasmon band, zeta potential, atomic absorption, stability, size and size distribution...
August 9, 2017: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/28801995/inst-ox-05-024-first-line-gemcitabine-oxaliplatin-and-erlotinib-for-primary-hepatocellular-carcinoma-and-bile-duct-cancers-a-multicenter-phase-ii-trial
#5
Yehuda Z Patt, Waheed Murad, Mohammed H Fekrazad, Ari D Baron, Pranshu Bansal, Yanis Boumber, Kim Steinberg, Sang-Joon Lee, Ed Bedrick, Ruofei Du, Fa Chyi Lee
Hepatocellular Carcinoma (HCC) incidence is increasing in the USA. Gemcitabine (G) and oxaliplatin (O) are active in HCC and biliary duct cancer (BDC). Erlotinib (E) is an EGFR tyrosine kinase inhibitor (TKI) with known activity against both. We sought to evaluate the efficacy of the combination G+O+E. Patients with either of the two diagnosis were treated in a phase II trial. Simons 2 stage design was used. A disease-control rate (DCR), complete response (CR) + partial response (PR)+ stable disease (SD) at 24 weeks of ≤20% and >40% (P0 and P1 of 0...
August 11, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28801183/paired-phase-ii-studies-of-erlotinib-bevacizumab-for-advanced-bronchioloalveolar-carcinoma-or-never-smokers-with-advanced-non-small-cell-lung-cancer-swog-s0635-and-s0636-trials
#6
Howard L West, James Moon, Antoinette J Wozniak, Philip Mack, Fred R Hirsch, Martin J Bury, Myron Kwong, Dorothy D Nguyen, Dennis F Moore, Jieling Miao, Mary Redman, Karen Kelly, David R Gandara
BACKGROUND: Before mutation testing of the epidermal growth factor receptor (EGFR) gene was recognized as highly associated with the activity of EGFR tyrosine kinase inhibitors (TKIs), clinically defined patient populations with bronchioloalveolar carcinoma (BAC) and never smokers were identified as likely to benefit from EGFR TKIs. From preclinical and clinical data suggesting potentially improved efficacy with a combination of an EGFR TKI and the antiangiogenic agent bevacizumab, the Southwestern Oncology Group (SWOG) initiated paired phase II trials to evaluate the combination of erlotinib/bevacizumab in patients with advanced BAC (SWOG S0635) or never smokers with advanced lung adenocarcinoma (SWOG S0636)...
July 6, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28798270/a-phase-i-dose-escalation-study-of-the-safety-and-pharmacokinetics-of-pictilisib-in-combination-with-erlotinib-in-patients-with-advanced-solid-tumors
#7
Stephen Leong, Rebecca A Moss, Daniel W Bowles, Joseph A Ware, Jing Zhou, Jill M Spoerke, Mark R Lackner, Geetha Shankar, Jennifer L Schutzman, Ruud van der Noll, Emile E Voest, Jan H M Schellens
BACKGROUND: Epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K) are involved in the proliferation and survival of many cancer types. Enhanced antitumor activity may be achieved through combined inhibition of these pathways. We report results for pictilisib (GDC-0941, a class I pan-PI3K inhibitor) plus erlotinib (an EGFR tyrosine kinase inhibitor) in patients with advanced solid tumors. MATERIALS AND METHODS: A 3 + 3 dose-escalation study was carried out at a starting daily dose of 60 mg pictilisib on days 1-21 of a 28-day cycle and 150 mg erlotinib from day 2 of cycle 1...
August 10, 2017: Oncologist
https://www.readbyqxmd.com/read/28794650/treating-egfr-mutation-resistance-in-non-small-cell-lung-cancer-role-of-osimertinib
#8
REVIEW
Valentina Mazza, Federico Cappuzzo
The discovery of mutations in EGFR significantly changed the treatment paradigm of patients with EGFR-mutant non-small cell lung cancer (NSCLC), a particular group of patients with different clinical characteristics and outcome to EGFR-wild-type patients. In these patients, the treatment of choice as first-line therapy is first- or second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, or afatinib. Inevitably, after the initial response, all patients become refractory to these drugs...
2017: Application of Clinical Genetics
https://www.readbyqxmd.com/read/28794648/cost-analysis-of-adverse-events-associated-with-non-small-cell-lung-cancer-management-in-france
#9
Christos Chouaid, Delphine Loirat, Emilie Clay, Aurélie Millier, Chloé Godard, Amira Fannan, Laurie Lévy-Bachelot, Eric Angevin
BACKGROUND: Adverse events (AEs) related to medical treatments in non-small cell lung cancer (NSCLC) are frequent and need an appropriate costing in health economic models. Nevertheless, data on costs associated with AEs in NSCLC are scarce, particularly since the development of immunotherapy with specific immune-related AEs. OBJECTIVE: To estimate the costs of grades 3 and 4 AEs related to NSCLC treatments including immunotherapy in France. METHODS: Grades 3 and 4 AEs related to treatment and reported in at least 1% of patients in Phase III clinical trials for erlotinib, ramucirumab plus docetaxel, docetaxel, pemetrexed plus carboplatin plus bevacizumab, platinum-based chemotherapies, nivolumab and pembrolizumab were identified...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28794368/interstitial-lung-disease-induced-by-osimertinib-for-epidermal-growth-factor-receptor-egfr-t790m-positive-non-small-cell-lung-cancer
#10
Yoshiya Matsumoto, Tomoya Kawaguchi, Norio Yamamoto, Kenji Sawa, Naoki Yoshimoto, Tomohiro Suzumura, Tetsuya Watanabe, Shigeki Mitsuoka, Kazuhisa Asai, Tatsuo Kimura, Naruo Yoshimura, Yuko Kuwae, Kazuto Hirata
A 75-year-old man with stage IV lung adenocarcinoma was treated with osimertinib due to disease progression despite having been administered erlotinib. Both an epidermal growth factor receptor (EGFR) L858R mutation on exon 21 and a T790M mutation on exon 20 were detected in a specimen from a recurrent primary tumor. Five weeks after osimertinib initiation, he developed general fatigue and dyspnea. Chest computed tomography scan revealed diffuse ground glass opacities and consolidation on both lungs. An analysis of the bronchoalveolar lavage fluid revealed marked lymphocytosis, and a transbronchial lung biopsy specimen showed a thickened interstitium with fibrosis and prominent lymphocytic infiltration...
August 10, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28794362/synchronous-duodenal-cancer-and-lung-cancer-harboring-an-epidermal-growth-factor-receptor-mutation-treated-with-erlotinib-and-oral-fluoropyrimidine
#11
Norimichi Akiyama, Masato Karayama, Moriya Iwaizumi, Yukiko Kusama, Masato Kono, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Takafumi Suda
Chemotherapy for multiple primary cancers is challenging. We describe a case of synchronous duodenal cancer with lung cancer harboring an epidermal growth factor receptor (EGFR) mutation treated with erlotinib and S-1, an oral fluoropyrimidine agent. A 78-year-old woman with advanced EGFR-mutated lung adenocarcinoma was simultaneously diagnosed with duodenal adenocarcinoma. After the treatment with erlotinib, the lung cancer responded well, but her duodenal cancer showed no response. S-1 was added to erlotinib, and the duodenal cancer demonstrated a good response with tolerable toxicities...
August 10, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28792525/a-data-mining-approach-for-identifying-pathway-gene-biomarkers-for-predicting-clinical-outcome-a-case-study-of-erlotinib-and-sorafenib
#12
David G Covell
A novel data mining procedure is proposed for identifying potential pathway-gene biomarkers from preclinical drug sensitivity data for predicting clinical responses to erlotinib or sorafenib. The analysis applies linear ridge regression modeling to generate a small (N~1000) set of baseline gene expressions that jointly yield quality predictions of preclinical drug sensitivity data and clinical responses. Standard clustering of the pathway-gene combinations from gene set enrichment analysis of this initial gene set, according to their shared appearance in molecular function pathways, yields a reduced (N~300) set of potential pathway-gene biomarkers...
2017: PloS One
https://www.readbyqxmd.com/read/28791489/metalloprotease-dependent-activation-of-egfr-modulates-cd44-cd24-populations-in-triple-negative-breast-cancer-cells-through-the-mek-erk-pathway
#13
Randi Wise, Anna Zolkiewska
PURPOSE: The CD44(+)/CD24(-) cell phenotype is enriched in triple negative breast cancers, is associated with tumor invasive properties, and serves as a cell surface marker profile of breast cancer stem-like cells. Activation of Epidermal Growth Factor Receptor (EGFR) promotes the CD44(+)/CD24(-) phenotype, but the specific signaling pathway downstream of EGFR responsible for this effect is not clear. The purpose of this study was to determine the role of the MEK/ERK pathway in the expansion of CD44(+)/CD24(-) populations in TNBC cells in response to EGFR activation...
August 8, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28790264/-a-case-of-lung-adenocarcinoma-presenting-with-leptomeningeal-carcinomatosis-successfully-treated-with-afatinib-after-erlotinib-induced-hepatotoxicity
#14
Hiroaki Tanaka, Minehiko Inomata, Ryuji Hayashi, Kazuki Shimokawa, Kotaro Tokui, Seisuke Okazawa, Kenta Kambara, Toru Yamada, Toshiro Miwa, Tatsuhiko Kashii, Hirofumi Konishi, Kazuyuki Tobe
A 65-year-old man was diagnosed with leptomeningeal carcinomatosis based on the findings of cerebrospinal fluid cytology and magnetic resonance imaging(MRI).Treatment with erlotinib and bevacizumab was initiated, and partial improvement in consciousness and MRI findings were obtained.However, it was difficult to continue the treatment because of elevation in levels of liver enzymes and melena.We switched the treatment to afatinib monotherapy, and his consciousness improved immediately.Progression -free survival and overall survival from the initiation of the treatment with afatinib were 7 and 9...
July 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28790147/hepatocyte-specific-deletion-of-egfr-in-mice-reduces-hepatic-abcg2-transport-activity-measured-with-11-c-erlotinib-and-positron-emission-tomography
#15
Alexander Traxl, Karin Komposch, Elisabeth Glitzner, Thomas Wanek, Severin Mairinger, Oliver Langer, Maria Sibilia
The epidermal growth factor receptor (EGFR) regulates cellular expression levels of breast cancer resistance protein (humans: ABCG2, rodents: Abcg2) via its downstream signaling pathways. Drugs that inhibit EGFR signaling (e.g. tyrosine kinase inhibitors, antibodies) may lead to ABCG2-mediated drug-drug interactions (DDIs) by changing disposition of concomitantly administered ABCG2 substrate drugs. In this study we used positron emission tomography (PET)/magnetic resonance (MR) imaging to compare disposition of the model Abcg2 substrate [(11)C]erlotinib in a mouse model of hepatocyte-specific deletion of EGFR (EGFR(Δhep) mice, n = 5) with EGFR(fl/fl) control mice (n = 6), which have normal EGFR expression levels in all tissues...
August 8, 2017: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/28776965/silicon-phthalocyanines-axially-disubstituted-with-erlotinib-towards-small-molecular-target-based-photodynamic-therapy
#16
Juan-Juan Chen, Yi-Zhen Huang, Mei-Ru Song, Zhi-Hong Zhang, Jin-Ping Xue
Small molecular target-based photodynamic therapy-a promising targeted anticancer strategy-has been developed by the conjugation between zinc (II) phthalocyanine and small molecular target-based anticancer drug. To inhibit the self-aggregation and avoid the isomeride problem of phthalocyanine, two silicon phthalocyanines di-substituted axially with erlotinib have been synthesized and fully characterized. These conjugates exist as a monomeric form in different solvents and the culture media. Cellular experiments showed that these conjugates localize in lysosomes and mitochondria, and keep high photodynamic activities (IC₅₀ is as low as 8 nM under 1...
August 4, 2017: ChemMedChem
https://www.readbyqxmd.com/read/28775148/the-tumor-suppressor-protein-opcml-potentiates-anti-egfr-and-anti-her2-targeted-therapy-in-her2-positive-ovarian-and-breast-cancer
#17
Elisa Zanini, Louay S Louis, Jane Antony, Evdoxia Karali, Imoh S Okon, Arthur B McKie, Sebastian Vaughan, Mona El-Bahrawy, Justin Stebbing, Chiara Recchi, Hani Gabra
OPCML is a tumor suppressor gene that is frequently inactivated in ovarian cancer and many other cancers by somatic methylation. We have previously shown that OPCML exerts its suppressor function by negatively regulating a spectrum of receptor tyrosine kinases (RTKs), such as ErbB2/HER2, FGFR1 and EphA2, thus attenuating their related downstream signaling. The physical interaction of OPCML with this defined group of RTKs is a prerequisite for their downregulation. Overexpression/gene amplification of EGFR and HER2 is a frequent event in multiple cancers including ovarian and breast cancers...
August 3, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28774860/pulse-dose-erlotinib-and-zuckerguss-improvement-in-egfr-mutant-nsclc
#18
Pareen Mehta, Omid Hamid, Samuel J Klempner
No abstract text is available yet for this article.
July 31, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28772281/randomised-phase-2-study-of-maintenance-linsitinib-osi-906-in-combination-with-erlotinib-compared-with-placebo-plus-erlotinib-after-platinum-based-chemotherapy-in-patients-with-advanced-non-small-cell-lung-cancer
#19
Tudor-Eliade Ciuleanu, Samreen Ahmed, Joo-Hang Kim, Jörg Mezger, Keunchil Park, Michael Thomas, Jihong Chen, Srinivasu Poondru, Jan M VanTornout, Debbie Whitcomb, Fiona Blackhall
BACKGROUND: Maintenance therapy is important in advanced/metastatic non-small cell lung cancer (NSCLC). Erlotinib as switch maintenance following platinum-based chemotherapy increases survival. Cross-talk between the epidermal growth factor receptor and insulin-like growth factor receptor (IGFR) pathways mediate resistance to individual receptor blockade. This study compared maintenance linsitinib plus erlotinib vs erlotinib plus placebo in patients with NSCLC. METHODS: In this Phase II randomised trial, patients without progression following four cycles of first-line platinum-based chemotherapy (N=205) received continuous schedule maintenance oral linsitinib 150 mg or placebo BID combined with erlotinib 150 mg QD for 21-day cycles...
August 3, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28767402/mimicking-the-bim-bh3-domain-overcomes-resistance-to-egfr-tyrosine-kinase-inhibitors-in-egfr-mutant-non-small-cell-lung-cancer
#20
Jinjing Xia, Hao Bai, Bo Yan, Rong Li, Minhua Shao, Liwen Xiong, Baohui Han
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are widely applied to treat EGFR-mutant non-small cell lung cancer (NSCLC). BIM is a BH3 domain-containing protein encoded by BCL2L11. Some EGFR-mutant NSCLC patients showing BIM deletion polymorphism are resistant to EGFR TKIs. We retrospectively investigated BIM deletion polymorphism in NSCLC patients, its correlation with EGFR TKI (erlotinib) resistance, and the mechanism underlying the drug resistance. Among 245 EGFR-mutant NSCLC patients examined, BIM deletion polymorphism was detected in 43 (12...
July 20, 2017: Oncotarget
keyword
keyword
8876
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"